Worth reading
41Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Announced details
Telomelysin
Launch date7 April 2026 (publication commenced; actual)
Relationship between the counterparty and the company
Oncolys BioPharma Inc.4588
Relationship with the Company
Relationship concerning the preparation and publication of an analyst report on our company. Capital and personal relationships: not disclosed
Counterpartyフェアリサーチ社
A third-party research and analysis firm that prepared the analyst report. Other details: not disclosed
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Source (materials cited by the company)
Analyst report by フェアリサーチ社
| Item | Details |
|---|---|
| Names of Products / Services Covered | Telomelysin |
| Counterparty | フェアリサーチ社 |
| Counterparty overview | A third-party research and analysis firm that prepared the analyst report. Other details: not disclosed |
| Relationship with the Company | Relationship concerning the preparation and publication of an analyst report on our company. Capital and personal relationships: not disclosed |
| Launch date | 7 April 2026 (publication commenced; actual) |
| Source | Analyst report by フェアリサーチ社 |
Items this document does not state (12)
Contract ValueOffering priceContract DateApplicable areaAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To publish a report based on research and analysis from a third-party perspective and deepen stakeholders’ understanding of our business.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.